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Abstract
Aims: The vasopressin V2 receptor antagonist, tolvaptan, has been reported to be effec-
tive in cirrhotic patients with ascites. Here, we evaluated predictors of the response to 
tolvaptan. Methods: A total of 97 patients with cirrhosis (60 males; median age, 63 years) 
who had been treated for ascites with oral tolvaptan were enrolled. Tolvaptan efficacy 
was defined as urine volume increase of ≥500 mL or a urine volume ≥2000 mL/day on the 
day following treatment. Normalization of the serum sodium (Na) level after 1 week of 
treatment and the posttreatment survival rate was analyzed. Results: Tolvaptan therapy 
resulted in effective urination in 67% of patients. A multivariate analysis revealed that 
the blood urea nitrogen/creatinine (BUN/Cr) ratio and urinary Na/potassium (Na/K) 
ratio were predictive of the tolvaptan response (p <0.05). The serum Na level was 135 
(121–145) mEq/L, and normal levels were recovered in 50.0% of the patients with an 
initial Na level of <135 mEq/L. The posttreatment survival rate was significantly higher 
in patients who responded to tolvaptan therapy (p <0.05). Conclusions: The combination 
of the initial BUN/Cr and urine Na/K ratios and a normalized serum Na level after 1 
week was predictive of a favorable outcome to tolvaptan therapy.
Keywords: vasopressin V2 receptor antagonist, tolvaptan, blood urea nitrogen/creatinine 
ratio, urine sodium/potassium ratio, serum sodium
1. Introduction
Ascites accumulation is commonly observed in decompensated liver cirrhosis [1]. The symptoms 
of ascites lead to a poor quality of life and prognosis [2]. Recently, the vasopressin V2 receptor 
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antagonist tolvaptan has been used for ascites treatment of cirrhosis in addition to spironolac-
tone ± furosemide [3, 4]. The Japanese Society of Gastroenterology published evidence-based 
clinical practice guidelines in 2015 [5]. Tolvaptan is recommended for use before ascites drainage 
or administration of albumin because of its high efficacy irrespective of the serum albumin level 
[6]. While the serum sodium (Na) level is low in cirrhosis, it is increased in tolvaptan-treated 
patients because of free water clearance without accompanying Na elimination. In contrast, con-
ventional diuretics promote hyponatremia and impair renal function. Thus, tolvaptan has ben-
efits for the treatment of cirrhosis.
The mechanism underlying refractory ascites caused by liver cirrhosis has been hypoth-
esized as one or more of the following [7, 8]: (1) hypo-osmotic pressure due to hypoalbumin-
emia; (2) a response to mesenteric and systemic vasodilation, accompanied by development 
of portal hypertension, which decreases the effective circulatory volume and depletes renal 
flow, leading to increased arginine vasopressin (AVP) release; increased AVP results in an 
increase in renin-angiotensin-aldosterone system activity; and (3) postsinusoidal obstruc-
tion and lymphatic edema. These multiple causative factors are associated with ascites 
accumulation.
Approximately 70% of tolvaptan-treated patients exhibit increased urination and achieve a 
reduction in body weight within 7–14 days [9, 10]. In addition to this short-term efficacy, 
tolvaptan also exerts long-term effects [11]. However, factors that predict the response to 
tolvaptan and its effect on prognosis are unclear. In this study, we focused on predictors of 
the tolvaptan response and the outcome of tolvaptan therapy.
2. Patients and methods
2.1. Patients
This was a single-center, retrospective observational study performed between September 
2013 and March 2016. We enrolled a total of 97 Japanese cirrhotic patients (60 males, 62%) 
who received tolvaptan 3.75–7.5 mg/day (Samsca™; Otsuka Pharmaceutical Co. Ltd., 
Tokyo, Japan) after hospitalization for ascites treatment. They were treated with conven-
tional diuretics.
2.2. Method
The patients were classified as responders or nonresponders to tolvaptan therapy. Tolvaptan 
efficacy was defined as a urine volume increase of ≥500 mL or a urine volume ≥2000 mL/
day on the day following tolvaptan treatment, as described by Ohki et al. with slight modi-
fications [12]. The baseline characteristics of patients, including age, sex, medications, and 
laboratory parameters, were evaluated. We investigated the changes in body weight and the 
serum Na level after 1 week of treatment and evaluated laboratory parameters. Tolvaptan 
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was not used in patients with severe renal dysfunction (estimated glomerular filtration rate 
<15 mL/min/1.73 m2 or a serum creatinine [Cr] level >3.5 mg/dL) or a hepatic coma scale 
score >II.
This study was conducted according to the principles of the Declaration of Helsinki, and 
the Institutional Review Board of Tokyo Women’s Medical University Hospital (Tokyo, 
Japan) approved the study protocol (no. 3258-R). The results of this study, including fig-
ures and tables, were published in Hepatology Research [13] and were transferred with 
permission.
2.3. Statistical analysis
Data are presented as medians with minimum and maximum values. Significant differ-
ences between the two groups were assessed using the Mann–Whitney U-test and χ2 test. 
The Statistical Package for the Social Sciences software (SPSS Institute, 11.01.J, Chicago, 
IL, USA) was used for the statistical analyses. Statistical significance was considered at 
p < 0.05.
3. Results
3.1. Response to tolvaptan according to urination and body weight parameters
The median age of the 97 patients (62% male) receiving tolvaptan treatment was 63 years 
(range, 22–90 years; Table 1). The underlying liver diseases and frequency of other ascites 
treatments did not differ significantly. The median increase in urine volume on the day 
after treatment was 690 mL (range: −530 to +3490 mL), while the median urine volume was 
1675 mL/day (range: 195–6630 mL/day). The distributions of urination and body weight 
changes and their correlations with the tolvaptan response are shown in Figure 1(a). The 
change in body weight after 1 week of treatment was −1.5 kg (−17.2 to +6.2 kg). A total 
urine volume ≥2000 mL was achieved in 40% of cases and an increase in the urine volume 
in ~50% of cases (Figure 1b). Approximately 40% of cases achieved a ≥2.0 kg body weight 
reduction after 1 week of treatment. Overall, 67% of the cases achieved the desired level 
of urination. In cases who responded to tolvaptan, the platelet count, urine Na level, and 
urine Na/potassium (K) ratio were higher, and the blood urea nitrogen (BUN)/Cr ratio was 
lower (Table 2). The serum Na level was 135 (121–145) mEq/L, and 39.2% of cases had an 
Na level of <135 mEq/L.
3.2. Urination-based predictors of the response to tolvaptan
Multivariate analysis revealed that the BUN/Cr ratio (odds ratio [OR], 1.08; 95% confidence 
interval [CI], 1.006–1.174; p < 0.05) and urine Na/K ratio (OR, 0.59; 95% CI, 0.366–0.855; p < 0.01) 
were predictors of the tolvaptan response (Table 3). In particular, patients who satisfied both 
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Figure 1. Urine volume and body weight response after tolvaptan treatment. (a) Distributions of urine volume after 
1 day, and change in body weight after 1 week, of tolvaptan treatment. Circle, responder; cross, nonresponder. (b) 
The percentage of urination and body weight reduction responded to a tolvaptan therapy. Urine volume 1 day after, 
and change in body weight 1 week after, tolvaptan treatment was correlated with the tolvaptan response (a). A body 
weight reduction of ≥2.0 kg was found in 40% of cases, and a urine volume ≥2000 mL and a urine volume increase ≥500 
mL were found in 67% of patients in response to tolvaptan therapy (b).
Total (n = 97) Responder (n = 65) Nonresponder (n = 32) p-value
Age (years) 63 (22–90) 62 (22–90) 63 (37–84) 0.21












20 (0–160) 20 (0–160) 20 (0–80) 0.96
Spironolactone dose 
(mg/day)
50 (0–400) 50 (0–400) 50 (0–400) 0.97
BCAA (%) 90 89 91 0.11
Administration of 
albumin (%)
62 63 59 0.65
CART or drainage (%) 41 38 47 0.43
Prognosis; death or 
transplantation (%)
45 37 63 0.03
Notes: PBC, primary biliary cholangitis; HCC, hepatocellular carcinoma; BCAA, branched-chain amino acid; CART, 
cell-free and concentrated ascites reinfusion therapy.
Table 1. Baseline characteristics of the patients.
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Total (n = 97) Responder (n = 65) Nonresponder (n = 32) p value
Albumin (g/dL) 2.5 (1.5–4.2) 2.5 (1.5–4.2) 2.4 (1.9–3.5) 0.88
Total bilirubin (mg/dL) 1.8 (0.3–52.4) 1.5 (0.5–33.0) 2.2 (0.3–52.4) 0.73
Platelet count (×104 μL−1) 8.6 (1.5–42.4) 9.0 (1.5–42.4) 6.4 (2.1–23.9) 0.05
Prothrombin time (%) 54.5 (16.3–90.3) 54.5 (16.3–90.3) 52.6 (22.6–89.0) 0.70
Ammonia (mg/dL) 69 (25–269) 70 (25–269) 63 (29–212) 0.97
α-Fetoprotein (ng/mL) 4 (1–29,292) 4 (1–4510) 6.5 (1–29,292) 0.36
DCP (mAU/mL) 75 (3–4994) 42 (3–4994) 324 (10–1788) 0.61
BUN (mg/dL) 23.4 (5.5–125.3) 21 (5.5–63.3) 27 (12.0–125.3) 0.02
Creatinine (mg/dL) 1.07 (0.20–3.30) 1.00 (0.42–2.12) 1.17 (0.50–3.30) 0.13
eGFR (mL/min/1.73 m2) 50.0 (15.0–250.6) 50.3 (18–250.6) 46.2 (15.0–108.6) 0.15
Serum Na (mEq/L) 135 (121–145) 136 (122–145) 133 (121–144) 0.06
Serum K (mEq/L) 4.2 (2.8–6.1) 3.9 (2.8–5.3) 4.3 (3.1–6.1) 0.06
Serum osmolarity 
(mOsm/L)
281 (100–317) 283 (100–317) 279 (256–299) 0.68
Urine osmolarity 
(mOsm/L)
404 (116–938) 405 (116–938) 388 (233–715) 0.63
Urinary Na (mEq/L) 61 (7–256) 69.5 (10–256) 39 (7–108) <0.01
Urinary K (mEq/L) 21 (6–72) 20 (6–72) 22 (13–48) 0.72
24 h creatinine clearance 
(mL/min)
51.2 (7.6–124.0) 52.8 (12.4–124.0) 44.1 (7.6–92.9) 0.12
BUN/creatinine ratio 22.5 (6.83–138.5) 21 (5.5–138.5) 23.7 (14.4–48.3) 0.01
Urine Na/K ratio 2.53 (0.22–25.6) 3.31 (0.35–25.6) 2.01 (0.22–5.13) <0.01
Child-pugh score 10 (7–14) 10 (7–13) 10 (8–14) 0.23
Model for end-stage liver 
disease score
14 (7–31) 14 (7–31) 16 (8–31) 0.37
Notes. DCP; des-γ-carboxy prothrombin, BUN; blood urea nitrogen; eGFR, estimated glomerular filtration rate; Na/K; 
sodium/potassium.
Table 2. Laboratory data at initiation of tolvaptan treatment.
Parameter Odds ratio 95% confidence interval p-value
BUN/Cr ratio 1.08 1.006–1.174 <0.05
Urine Na/K ratio 0.59 0.366–0.855 <0.01
Serum K 1.41 0.537–3.893 n.s
Serum Na 0.96 0.854–1.080 n.s
Platelet count 0.95 0.839–1.051 n.s
Notes. Na/K, sodium/potassium; n.s, not significant.
Table 3. Multivariate analysis of parameters predicting a urination response to tolvaptan therapy.




<3.09 (n= 47) ≥3.09 (n = 30)
BUN/Cr ratio <17.5 (n = 23) 10/12 (83.3%) 8/8 (100.0%)
≥17.5 (n = 64) 13/33 (39.4%) 19/22 (86.3%)
Notes. BUN/Cr, blood urea nitrogen/creatinine; Na/K, sodium/potassium.
Table 4. Response to tolvaptan according to BUN/Cr and urine Na/K ratios.
Figure 2. Distributions of the BUN/Cr ratio and urinary Na/K ratio and changes in urine volume and body weight. 
(a) Distributions of the BUN/Cr ratio and urinary Na/K ratio according to the tolvaptan response. Circle, responder, 
cross, nonresponder; framed square, BUN/Cr ratio ≥17.5, and urine Na/K ratio <3.09. Changes in (b) urine volume and (c) 
body weight in patients with and those without a BUN/Cr ratio ≥17.5 and urine Na/K ratio <3.09. Patients without a BUN/
Cr ratio ≥17.5 and urine Na/K ratio <3.09 showed greater reductions in urine volume after 1 day (b) and in body weight 
after 1 week of treatment (c). BUN/Cr, blood urea nitrogen/creatinine; Na/K, sodium/potassium, *p < 0.01, **p < 0.05.
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criteria of a BUN/Cr ratio <17.5 and urine Na/K ratio ≥3.09 achieved high tolvaptan response 
rates (n = 8, 100%; Table 4). In contrast, patients with a BUN/Cr ratio ≥17.5 and urine Na/K ratio 
<3.09 exhibited an extremely poor response (Figure 2a, framed area). In those patients who did 
not meet these criteria, urination and body weight reductions were observed (Figure 2b and c).
3.3. Prognosis after tolvaptan treatment
Regarding the mortality rate, 44 subjects died (45.4%). The survival rate was higher in patients 
who responded to tolvaptan therapy, as estimated by the Kaplan–Meier analysis (Figure 3a, 
p < 0.01). Patients with a BUN/Cr ratio <17.5 or urine Na/K ratio ≥3.09 showed a significantly 
higher survival rate than that of those who did not meet these criteria (Figure 3b, p < 0.05).
After 1 week of treatment, 70.1% of the patients achieved a normal serum Na level. These patients 
showed a significantly higher survival rate (p < 0.05). Among the patients with an initial Na level 
of <135 mEq/L (n = 38), 50.0% achieved a normal Na level after tolvaptan therapy and showed 
a significantly higher survival rate than that of patients without normalized Na levels (p < 0.05).
4. Discussion
The results suggest that the initial BUN/Cr and urine Na/K ratios and a normalized serum Na 
level after 1 week of treatment is predictive of a tolvaptan response in cirrhosis patients. The 
Figure 3. Survival rate of patients with and without a response to tolvaptan and the BUN/Cr and urine Na/K ratios. 
Patients who responded to tolvaptan therapy (a) and who did not have a BUN/Cr ratio ≥17.5 or urine Na/K ratio <3.09 
(b) showed a significantly higher survival rate compared with nonresponders. BUN/Cr, blood urea nitrogen/creatinine; 
Na/K, sodium/potassium, *p < 0.01, **p < 0.05.
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patients showing a response to tolvaptan in terms of increased urination or serum Na level 
had prolonged survival and a better prognosis.
Representative factors predicting a response to tolvaptan are shown in Table 5. Free water 
clearance [14], aquaporin-2/AVP [15], and urinary Na excretion [16] were reported to be pre-
dictors of a tolvaptan response in patients with cirrhosis. The combination of BUN/Cr and 
urine Na/K ratios was the first reported predictor of a tolvaptan response.
Regarding prognosis, tolvaptan reduced the rate of inhospital mortality [17] and evidenced 
longer mortality same as other diuretics in heart failure patients [18], although no study has 
assessed these parameters in cirrhotic patients. In our study, patients with a BUN/Cr <17.5 
or urine Na/K ≥3.09 showed high response rates. Approximately 50.0% of tolvaptan-treated 
patients reached a normal serum Na level after 1 week of tolvaptan therapy. Patients who 
responded to tolvaptan exhibited prolonged survival compared with those who did not. 
Tolvaptan may improve the prognosis.
Tolvaptan has been reported to delay the onset of end-stage renal disease and to be associated 
with a low rate of renal function deterioration [19, 20]. Therefore, early initiation of tolvaptan 
is recommended to protect renal function and improve prognosis.
However, our study had limitations because hepatocellular carcinoma (HCC) affects the mor-
tality rate of patients with cirrhosis. Therefore, HCC cases must be excluded from prognostic 
analyses.
Author Journal Year Predictor Disease
Imamura et al. [21] Circ J. 2013 Urine osmolality and 
percentage decrease in 
urine osmolarity
Heart failure




Okayama et al. [23] Am J Cardiovasc 
Drugs
2015 Blood urea nitrogen/
creatinine (BUN/Cr) ratio
Heart failure
Shimizu et al. [24] Nephrology (Carlton) 2015 Urine urea nitrogen/BUN 
ratio
Heart failure
Iwatani et al. [25] Nephron 2015 Urine osmolarity Chronic kidney 
disease
Miyaaki et al. [14] Biomed Rep. 2015 Free water clearance Liver cirrhosis
Nakanishi et al. [15] J Gastroenterol. 2016 Urinary AQP2/Cr ratio Liver cirrhosis
Chishina et al. [26] Dig Dis. 2016 Serum BUN and serum Cr Liver cirrhosis
Imamura et al. [27] Int J Mol Sci. 2016 Urine AQP2 Heart failure
Kogiso et al. [13] Hepatol Res. 2016 Serum BUN/Cr and urine 
sodium/potassium ratios
Liver cirrhosis
Table 5. Representative predictors of the response to tolvaptan therapy.
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5. Conclusion
In addition to the combination of an initial BUN/Cr ratio <17.5 and urine Na/K ratio ≥3.09, a 
normalized serum Na level after 1 week of tolvaptan therapy was predictive of a favorable 
outcome in cirrhotic patients with hyponatremia and ascites treated with tolvaptan.
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